Entecavir 0.5 mg tablets: Supply issue

Supply issue Active

Due to manufacturing constraints, Sandoz has advised of a temporary supply issue affecting entecavir 0.5 mg tablets (Pharmacode 2549301).

23 March 2023 Supply update

Entecavir Mylan will be available until June 2023 when Entecavir Sandoz is resupplied.

Alternative product listed 

We know that the ongoing availability of entecavir is important. We have sourced an alternative brand, Entecavir Mylan (Pharmacode 2649020), to ensure people using entecavir have continued access to funded treatment.

These tablets will be funded from 1 December 2022.

Schedule listing for entecavir(external link)

We expect this medicine to be available to patients from mid-December 2022. This coincides with when Entecavir Sandoz will become unavailable. People using Entecavir Sandoz will need to change to the alternative brand to continue to access this medicine.

Entecavir Mylan has the same active ingredient and works in the body the same way as Entecavir Sandoz. It has been approved by Medsafe for use in New Zealand. 

Key dates

1 December 2022

  • Entecavir Mylan 0.5 mg tablets funded

Mid-December 2022

  • Entecavir Sandoz 0.5 mg tablets out of stock
  • Entecavir Mylan 0.5 mg tablets available

June 2023

  • Re-supply of Entecavir Sandoz

Who to contact

If you have questions about the funding for this product, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

About Pharmac's role in supply management